DexCom Historical Cash Flow
| DXCM Stock | USD 137.87 3.87 2.89% |
Analysis of DexCom cash flow over time is an excellent tool to project DexCom Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 675.5 M or Other Cashflows From Financing Activities of 2.5 B as it is a great indicator of DexCom ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining DexCom Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DexCom Inc is a good buy for the upcoming year.
DexCom |
About DexCom Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in DexCom balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which DexCom's non-liquid assets can be easily converted into cash.
DexCom Cash Flow Chart
DexCom Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the DexCom Inc Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, DexCom's Total Cash From Operating Activities is very stable compared to the past year. As of the 25th of April 2024, Net Income is likely to grow to about 568.6 M, though Total Cashflows From Investing Activities is likely to grow to (445.9 M). Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by DexCom Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of DexCom operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from DexCom's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. At this time, DexCom's Total Cash From Operating Activities is very stable compared to the past year. As of the 25th of April 2024, Net Income is likely to grow to about 568.6 M, though Total Cashflows From Investing Activities is likely to grow to (445.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 389.2M | 364.8M | 236.6M | 248.4M | Depreciation | 102M | 155.9M | 186M | 195.3M |
DexCom cash flow statement Correlations
Click cells to compare fundamentals
DexCom Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DexCom cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (690.7M) | 371.8M | 235.4M | (410.3M) | (75.8M) | (72.0M) | |
| Free Cash Flow | 134.5M | 276.6M | 53.3M | 304.7M | 511.9M | 537.5M | |
| Change In Working Capital | 6.1M | (20.8M) | (132M) | 27.7M | 3.2M | 3.4M | |
| Begin Period Cash Flow | 1.1B | 446.4M | 818.2M | 1.1B | 643.3M | 675.5M | |
| Total Cashflows From Investing Activities | (1.0B) | (1.0B) | (216.1M) | (521.5M) | (469.4M) | (445.9M) | |
| Other Cashflows From Financing Activities | (1.2M) | 1.2B | (9.9M) | (17.3M) | 2.4B | 2.5B | |
| Depreciation | 48.7M | 67.1M | 102M | 155.9M | 186M | 195.3M | |
| Capital Expenditures | 180M | 199M | 389.2M | 364.8M | 236.6M | 248.4M | |
| Total Cash From Operating Activities | 314.5M | 475.6M | 442.5M | 669.5M | 748.5M | 785.9M | |
| Net Income | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 568.6M | |
| Total Cash From Financing Activities | 10.7M | 912.1M | 10.4M | (552.5M) | (318.6M) | (302.7M) | |
| End Period Cash Flow | 446.4M | 818.2M | 1.1B | 643.3M | 567.5M | 291.3M | |
| Change To Liabilities | 125M | 220.6M | 68.4M | 303.6M | 349.1M | 366.6M | |
| Other Non Cash Items | 51.7M | 93.6M | 209.3M | 39.8M | (78M) | (74.1M) | |
| Stock Based Compensation | 102.7M | 119.4M | 113.4M | 126.5M | 150.8M | 143.3M | |
| Change To Inventory | (49.1M) | (114.5M) | (112.2M) | 49.3M | (252.6M) | (240.0M) | |
| Change To Account Receivables | (60M) | (142.3M) | (75.5M) | (199.9M) | (260.1M) | (247.1M) | |
| Sale Purchase Of Stock | 11.9M | 15.3M | 20.3M | (557.7M) | (688.7M) | (654.3M) | |
| Investments | (835.2M) | (807.7M) | 193.2M | (138.5M) | (1.1B) | (1.1B) | |
| Change Receivables | (60M) | (142.3M) | (75.5M) | (199.9M) | (179.9M) | (170.9M) | |
| Net Borrowings | 389M | 836.6M | 906.2M | 1.2B | 1.4B | 1.4B | |
| Cash And Cash Equivalents Changes | (690M) | 369.7M | 236.8M | (404.5M) | (364.1M) | (345.8M) | |
| Cash Flows Other Operating | (9.8M) | 15.4M | 62.8M | (126.5M) | (113.9M) | (108.2M) | |
| Change To Netincome | 109M | (64.3M) | 242.3M | 145.9M | 167.8M | 84.3M | |
| Change To Operating Activities | 6.4M | 22.9M | (11M) | (128.9M) | (116.0M) | (110.2M) | |
| Issuance Of Capital Stock | 11.9M | 15.3M | 20.3M | 22.5M | 26.6M | 19.7M |
DexCom Investors Sentiment
The influence of DexCom's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in DexCom. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to DexCom's public news can be used to forecast risks associated with an investment in DexCom. The trend in average sentiment can be used to explain how an investor holding DexCom can time the market purely based on public headlines and social activities around DexCom Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
DexCom's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for DexCom's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average DexCom's news discussions. The higher the estimated score, the more favorable is the investor's outlook on DexCom.
DexCom Implied Volatility | 116.65 |
DexCom's implied volatility exposes the market's sentiment of DexCom Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if DexCom's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that DexCom stock will not fluctuate a lot when DexCom's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DexCom in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DexCom's short interest history, or implied volatility extrapolated from DexCom options trading.
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving together with DexCom Stock
| 0.67 | NXL | Nexalin Technology | PairCorr |
Moving against DexCom Stock
| 0.77 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
| 0.74 | NUWE | Nuwellis Financial Report 14th of May 2024 | PairCorr |
| 0.73 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
| 0.73 | NAOV | NanoVibronix | PairCorr |
| 0.66 | HSTM | HealthStream | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.